Related Experiment Video
Updated: May 20, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized
K A L Müller1, T Geisler, M Gawaz
1Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Universitätsklinikum Tübingen, Germany.
Insights
Standard antiplatelet drugs like clopidogrel show variable effectiveness. Elinogrel, a new drug, offers more consistent platelet inhibition, potentially improving outcomes for patients undergoing coronary procedures or with acute coronary syndrome.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Aspirin and clopidogrel are standard antiplatelet therapies post-coronary intervention or acute coronary syndrome.
- Significant interindividual variability in response to clopidogrel affects up to 44% of patients.
- Platelet function testing (PFT) has not consistently improved prognostic outcomes in guided therapy.
Purpose of the Study:
- To review the investigational drug elinogrel for personalized antiplatelet therapy.
- To highlight elinogrel's potential advantages over clopidogrel in managing ischemic events.
Main Methods:
- Review of existing literature on antiplatelet therapy and elinogrel.
- Comparison of elinogrel's pharmacological profile and clinical effects with clopidogrel.
Main Results:
- Elinogrel provides rapid, consistent, and complete platelet inhibition.
- Elinogrel demonstrates advantages over clopidogrel without significantly increasing bleeding risk.
- Poor response to standard agents can be addressed by alternative medications like elinogrel.
Conclusions:
- Elinogrel represents a promising option for personalized antiplatelet strategies.
- The drug may overcome limitations associated with clopidogrel's variable response.
- Further investigation into elinogrel's role in preventing ischemic events is warranted.
Abstract:
The antiplatelet therapy with aspirin and the ADP-receptor blocker clopidogrel is currently the standard medication after coronary intervention or after acute coronary syndrome to prevent recurrent ischemic events and reduce mortality. However, high interindividual response variability to antiplatelet treatment is described in up to 44% of treated patients. A poor response to clopidogrel is caused by multifactorial mechanisms. Individual risk assessment including platelet function testing (PFT) can help to identify high risk patients, although recent randomized trials to investigate effects of PFT-guided therapy have failed to detect an impact on prognostic outcome. Poor response to standard antiplatelet agents can be overcome by switching to alternate substances. Elinogrel is a novel competitive, reversible ADP-receptor antagonist available in oral and intravenous formulation. Additional treatment with elinogrel showed advantages over clopidogrel, including more rapid, less variable, and more complete inhibition of platelet function without significantly increased bleeding complications. This review gives an overview over the investigational drug elinogrel for use in a personalized antiplatelet approach.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:27Peripheral Artery Disease III: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...